亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

POS0271 INFLIXIMAB FOR PARENCHYMAL NEURO-BEHÇET’S SYNDROME: A META-ANALYSIS

英夫利昔单抗 医学 病理 疾病
作者
Wenjie Zheng,Xiao Wang,Yan Liu,Yiyuan Ao,Jinling Wang,J. Liu,Yan Xu
标识
DOI:10.1136/annrheumdis-2024-eular.2748
摘要

Background:

Behçet's syndrome (BS) is a chronic, recurrent systemic vasculitis that can affect multiple systems. Neuro-Behçet's syndrome (NBS), especially parenchymal NBS(p-NBS), results in severe neurological sequelae with poor prognosis, ranging from cognitive changes to paralysis, which remains a challenging clinical issue.

Objectives:

This study aimed to evaluate the efficacy and safety of infliximab (IFX), a type of anti-TNF-α agents, in treating patients with p-NBS and hopefully provide a detailed time analysis for the IFX effect timeline in NBS treatment.

Methods:

We conducted this meta-analysis following the PRISMA guidelines. PubMed, Embase, Cochrane Library and Web of Science were systematically searched using the following logics: Behçet's syndrome (all synonyms) AND Infliximab (all synonyms) AND ('neuro' OR 'neurological' OR 'neurologic), and we also included the data from our institution in this meta-analysis. Therapeutic efficacy was evaluated by the improvement of clinical symptoms and radiological lesions, and clinical improvement was specifically defined as complete remission (CR), partial remission (PR) and no response (NR) [1,2]. We evaluated the efficacy of IFX at 3, 6, and 12 months respectively. The results were presented as forest plots with 95% confidence intervals. Besides, the details of adverse drug reactions were recorded.

Results:

8 studies involving a total of 77 patients were identified to perform the meta-analysis by adding the results from our institution. The pooled efficacy of IFX in treating p-NBS patients were analyzed. Clinical complete remission was achieved in 14.7% (95%CI 0.00-83.5%) of patients at Month 3, 28.7% (95% CI 0.00-86.7%) of patients at Month 6, 54.4% (95%CI 13.9-92.3%) at Month 12. Clinical partial remission was achieved in 97.0% (95%CI 61.9-100%) of patients at Months 3, 89.6% (95%CI 45.9-100%) of patients at Months 6, 100.0% (95%CI 96.0-100%) at Months 12. MRI improvement was achieved in 100.0% (95%CI 89.7-100%) of patients at Month 3, 89.1% (95% CI 26.3-100%) of patients at Month 6, 99.5% (95% CI 96.0-100%) at Month 12. The time-phase analysis indicated that IFX exerted its effect within 3 months and was sustained during the long term. Safety information was reported in 16 patients. Among them, 9% of patients experienced severe adverse events (AEs), no AE-related deaths were reported.

Conclusion:

IFX is an effective treatment option for p-NBS, and the incidence of severe AEs was acceptable. A comprehensive evaluation should be performed after three months of medication to determine the need for adjustments in subsequent therapy. Further well-designed, large-scale RCTs are needed to verify our findings.

REFERENCES:

[1] Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. [2] Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behçet's disease: A case series and review of the literature. Arthritis Care and Research 2008;59:285-90. (Article).

Acknowledgements:

We thank all the participants and their families.

Disclosure of Interests:

None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
ZaZa完成签到,获得积分10
8秒前
wyuanhu完成签到,获得积分10
13秒前
小芭乐完成签到 ,获得积分10
13秒前
奋斗的舒芙蕾完成签到,获得积分10
18秒前
22秒前
开心的瘦子完成签到,获得积分20
28秒前
JOSIELO完成签到 ,获得积分10
28秒前
29秒前
33秒前
程小柒完成签到 ,获得积分10
38秒前
40秒前
46秒前
Ghiocel完成签到,获得积分10
57秒前
1分钟前
佟语雪完成签到,获得积分10
1分钟前
轻松的惜芹应助喂喂采纳,获得10
1分钟前
淳于如雪发布了新的文献求助10
1分钟前
LLL完成签到 ,获得积分10
1分钟前
yar应助淳于如雪采纳,获得10
1分钟前
Koking关注了科研通微信公众号
1分钟前
1分钟前
淳于如雪完成签到,获得积分20
1分钟前
lv发布了新的文献求助10
1分钟前
我是老大应助吴嘉俊采纳,获得10
1分钟前
1分钟前
在水一方应助阿九采纳,获得10
1分钟前
1分钟前
ZT完成签到,获得积分10
1分钟前
搜集达人应助zhouleiwang采纳,获得10
1分钟前
吴嘉俊发布了新的文献求助10
1分钟前
仙人掌王朝完成签到,获得积分10
1分钟前
1分钟前
Hello应助zhouleiwang采纳,获得10
1分钟前
阿九完成签到,获得积分10
1分钟前
lllxxx完成签到 ,获得积分10
1分钟前
lv发布了新的文献求助10
1分钟前
冉亦完成签到,获得积分10
1分钟前
WGS完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216